Magazine

“In a business that’s constantly changing, there are always areas for improvement,” said Cathleen Biga, RN, MSN, a member of the Cardiovascular Business editorial advisory board. Cathie shared the sentiment with my colleague Daniel Allar, who was interviewing her about the upcoming American College of Cardiology Cardiovascular Summit that she co-directs and we’ll be attending.

Paying for call coverage isn’t always an option and, even when it is, sometimes it’s more bandage than cure. The priority should be addressing long-term physician satisfaction.

The days of physicians saying, “I want this” are fading fast, if not gone, in many locations, as hospitals restructure purchasing around committee decision making and formal processes.

The cardiology community is paying close attention to developments related to transcatheter mitral valve replacement (TMVR) for mitral regurgitation. Although TMVR is in its infancy, one big question on everyone’s minds is whether its impact will be on the same scale as transcatheter aortic valve replacement (TAVR).

Could the ORBITA trial’s enduring value be in prompting the cardiology community to rethink how it diagnoses, treats and even defines angina?

A small but growing number of survivorship clinics for congenital heart disease (CHD) patients are popping up in healthcare systems across the country, but some cardiologists wonder if the model is sustainable.

Known for its conservative and what many call risk-averse nature, the Food and Drug Administration (FDA) seems to be headed in a bold and ambitious direction under Commissioner Scott Gottlieb, MD. What will his leadership mean for cardiology?

By targeting inefficiencies, a quality improvement program led to gains of approximately five or more hours per day in cath lab time. The approach could work as a model for other practices.

The unrelenting growth of diabetes around the world is prompting cardiologists to rethink how they treat and manage a challenging patient population, even as an emerging class of cardio-protective diabetes drugs is setting the stage for transformation.

When third-grader Ava Rao was diagnosed with type 1 diabetes, it changed life for her whole family. Now a high school freshman, Ava and her dad, cardiologist Sunil V. Rao, MD, share their perspectives on the disease and hopes for the future. 

As Cardiovascular Business enters its second decade, our team has been pondering what the magazine’s pre-teen and teen years will be like. Are we looking at dignified maturity or awkward adolescence? 

Cardiologists are receiving more exposure to different imaging modalities during their fellowships, but their job prospects and training vary widely. A more comprehensive and multimodality training approach could lead to better results.  

Select an Issues